2C-T-7
2,5-dimethoxy-4-propylthiophenethylamine
Viewing r1 — Apr 26, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
2C-T-7 (2,5-dimethoxy-4-(n)-propylthiophenethylamine) — Beautiful, Blue Mystic, T7 — is a synthetic psychedelic of the phenethylamine class. It is a structural relative of mescaline with an added sulfur-containing side chain at the 4-position of its ring. It activates serotonin receptors in the brain, loosening normal sensory filtering and producing the visual and introspective effects characteristic of classical psychedelics.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
DOI, 2C-B, mescaline +2 moreDOI, 2C-B, mescaline, LSD, psilocybin show less
Alexander Shulgin first synthesized 2C-T-7 in 1986, naming it one of his six most important phenethylamines.[1] It spread from Dutch smart shops in the late 1990s to the United States, where three deaths in 2000–2001 prompted emergency federal scheduling.[2] It is now Schedule I in the United States and controlled internationally.[3]
Subjective effects include geometric visual patterns, brightened colors, empathogenic warmth, prosocial openness, and introspective depth.[4][5] The experience has a crystalline warmth that Shulgin considered distinct from Mescaline and LSD — closer to emotional opening than raw visual intensity.[1] Nausea during the slow onset and anxiety at higher doses are the most common unwanted effects.[2]
2C-T-7 produces no physical dependence and rapid tolerance limits compulsive use[6] — but three deaths are documented, all under high-risk conditions.[2] The main danger is combination: it activates serotonin receptors and slows serotonin breakdown simultaneously, so mixing it with MDMA or monoamine oxidase inhibitors can cause life-threatening overheating.[7] No clinical studies exist; what is known rests on animal pharmacology, Shulgin's self-reports, and informal surveys.
History[edit]
Discovery
Alexander Shulgin first synthesized 2C-T-7 in 1986, beginning with inactive test doses before reaching full psychedelic effects at 20–25 mg.[1] He documented it in PiHKAL as one of his "magical half-dozen" — the six phenethylamines he considered most important, alongside mescaline, 2C-B, and 2C-T-2.[1]
Recreational Circulation and Fatalities
2C-T-7 entered recreational use in the late 1990s through Dutch smart shops before spreading to the United States.[2] Between late 2000 and April 2001, three deaths were associated with the compound — all involving insufflated doses of ≥30 mg and/or co-ingestion of MDMA or stimulants.[8][2][9]
Scheduling
The DEA placed 2C-T-7 into temporary Schedule I on September 20, 2002,[10] then permanently on March 18, 2004.[3] The EU followed with control measures through Council Decision 2003/847/JHA,[11] following an EMCDDA risk assessment in 2003.[12]
The "2C" prefix, coined by Shulgin, denotes the two-carbon chain between the phenyl ring and amino group shared by all members of the series.[1] "T-7" marks it as the seventh thio-substituted compound in his systematic 4-position exploration. Street names that circulated during its brief market appearance included "Beautiful," "Blue Mystic," "Tripstay," and "Tweety-Bird Mescaline".[2]
Chemistry[edit]
Structural Class
2C-T-7 belongs to the 2C phenethylamine family — a group sharing the same basic molecular scaffold as mescaline. Within that family, the 2C-T subclass is defined by a sulfur atom at the 4-position of the aromatic ring; 2C-T-7 specifically carries a three-carbon (propylthio) chain there, distinguishing it from 2C-T-2 (two-carbon chain) and 2C-B (bromine). Its molecular formula is C₁₃H₂₁NO₂S (255.38 g/mol).
The sulfur atom makes it more fat-soluble than oxygen- or halogen-substituted analogs,[13] which affects both receptor binding and how the body processes it.
Pharmacology[edit]
Mechanism of Action
2C-T-7 activates serotonin receptors as a partial agonist — the same primary mechanism as LSD and mescaline. Animal studies confirmed this directly: animals given 2C-T-7 responded identically to those given a reference serotonin receptor activator, and blocking those receptors fully cancelled the effect.[14][15][16][17][18]
MAO Inhibition
Unlike most psychedelic phenethylamines, 2C-T-7 also slows the breakdown of serotonin, dopamine, and norepinephrine by inhibiting the enzymes (MAO-A and MAO-B) that normally clear them.[7] Activating serotonin receptors while simultaneously slowing serotonin breakdown creates a compounding load not present with 2C-B or Mescaline.
Pharmacokinetics
The body breaks down 2C-T-7 primarily through those same MAO enzymes, with the liver's CYP2D6 enzyme playing a secondary role.[19] No human pharmacokinetic data exist — onset, bioavailability, and elimination have not been measured in controlled settings. In rats, the main breakdown routes involve modification of the propyl side chain and detachment of the sulfur group.[20][21]
Neuroscience[edit]
Where It Acts
No brain imaging studies have been conducted with 2C-T-7. Based on its confirmed serotonin receptor activation,[14][15][16] it likely acts on the prefrontal cortex, reducing the brain's normal filtering of incoming sensory information and allowing more raw perception to shape experience.citation needed
Why It Matters
The monoamine oxidase-inhibiting properties may simultaneously elevate serotonin, dopamine, and norepinephrine,[7] likely contributing to the stimulant-like energy and empathogenic warmth users report.[4]
Psychedelics that activate serotonin receptors are known to promote growth of new brain connections.citation needed Whether 2C-T-7 shares this property has not been tested, but the effect has been demonstrated for closely related phenethylamines.
- Does 2C-T-7 promote structural neuroplasticity, and at what doses?
- How does its combined serotonin receptor agonist / MAO inhibitor profile affect brain dynamics compared to pure serotonin receptor agonists like LSD?
- Does the 8–15 hour duration reflect slow receptor unbinding, sustained blood levels, or both?
- What accounts for the empathogenic warmth not prominent in structurally similar 2C-B?
Subjective Effects[edit]
2C-T-7 produces a psychedelic state with an unusual emotional warmth at its center. Geometric visuals and perceptual shifts appear alongside prosocial openness — a combination that feels more emotionally resonant than most phenethylamines.[4][5]
Among the 2C phenethylamines, 2C-T-7 sits closer to mescaline in introspective character than to the shorter, more visually focused 2C-B. Shulgin considered its "crystalline" thought quality and emotional openness qualitatively distinct from most compounds in its class[1] — though these characterizations rest on self-report rather than controlled comparison.
Effect Grid
At common oral doses (15–25 mg), the full psychedelic experience manifests: pronounced colour enhancement and saturation, geometric visual patterning overlaying surfaces, drifting and morphing of objects, and closed-eye visuals with intricate detail. Empathogenic and prosocial effects become prominent — a quality Shulgin specifically noted as distinguishing 2C-T-7 from other phenethylamines. Thought connectivity and introspection deepen, with a reported "crystalline" clarity.
Nausea is one of the most common adverse effects at this range, typically peaking during the come-up (1–2 hours post-ingestion). Muscle tension, jaw clenching, and stimulatory cardiovascular effects (increased heart rate, mild blood pressure elevation) are frequently reported. Duration is 8–12 hours; sleep is unlikely for the first 10–12 hours.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Holotropic state · Tracers · Environmental patterning · Music enhancement · Visual breathing · Touch enhancement · After-images · Symmetrical texture repetition · Auditory enhancement · Brightness alteration · Depth perception distortion · Light sensitivity · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Sound sensitivity · Visual melting · Visual morphing · Auditory distortion · Auditory misinterpretation · Peripheral misidentification · Spatial disorientation · Vestibular distortion · Visual diffraction · Visual haze / noise · Dreaming enhancement · Synesthesia · Visual acuity suppression · Visual magnification · Visual processing acceleration · Visual acuity enhancement · Flashbacks · Object transformations · Internal hallucinations · Environmental orbism / cubism · External hallucinations · Object activation · Auditory hallucinations · Perspective hallucinations · Visual processing suppression · Visual recursion · Visual scenery slicing · Persisting hallucinations
Visual breathing · Touch enhancement · After-images · Symmetrical texture repetition · Auditory enhancement · Brightness alteration · Depth perception distortion · Light sensitivity · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Sound sensitivity · Visual melting · Visual morphing · Auditory distortion · Auditory misinterpretation · Peripheral misidentification · Spatial disorientation · Vestibular distortion · Visual diffraction · Visual haze / noise · Dreaming enhancement · Synesthesia · Visual acuity suppression · Visual magnification · Visual processing acceleration · Visual acuity enhancement · Flashbacks · Object transformations · Internal hallucinations · Environmental orbism / cubism · External hallucinations · Object activation · Auditory hallucinations · Perspective hallucinations · Visual processing suppression · Visual recursion · Visual scenery slicing · Persisting hallucinations
Wakefulness · Body high · Spontaneous body sensations · Body schema distortion · Muscle tension · Appetite suppression · Dizziness · Excessive sweating · Bruxism · Bodily heaviness · Bodily pressures · Dry mouth · Heart rate perception changes · Insomnia · Laughter fits · Physical fatigue · Restlessness · Tactile euphoria · Tingling / electric sensations · Vibrations / buzzing · Headache · Involuntary body movements · Dehydration sensation · Breathing alteration · Sexual arousal enhancement · Trembling · Vasoconstriction · Vomiting · Diarrhea · Increased urination · Watery eyes · Bodily lightness · Salivation · Sedation · Yawning · Abnormal heartbeat · Bodily dissociation · Tactile hallucination
Body schema distortion · Muscle tension · Appetite suppression · Dizziness · Excessive sweating · Bruxism · Bodily heaviness · Bodily pressures · Dry mouth · Heart rate perception changes · Insomnia · Laughter fits · Physical fatigue · Restlessness · Tactile euphoria · Tingling / electric sensations · Vibrations / buzzing · Headache · Involuntary body movements · Dehydration sensation · Breathing alteration · Sexual arousal enhancement · Trembling · Vomiting · Diarrhea · Increased urination · Watery eyes · Bodily lightness · Salivation · Sedation · Yawning · Abnormal heartbeat · Bodily dissociation · Tactile hallucination
Conceptual thinking · Aesthetic enhancement · Thought acceleration · Cognitive euphoria · Cognitive flexibility · Introspection enhancement · Multiple thought streams · Openness enhancement · Thought connectivity · Memory suppression · Thought loops · Cognitive fatigue · Cognitive impairment · Confusion · Focus suppression · Increased nature relatedness · Information processing suppression · Memory fragmentation · Thought disorganization · Analysis enhancement · Creativity enhancement · Analysis suppression · Cognitive dysphoria · Humor enhancement · Motivation suppression · Synchronicity · Language suppression · Memory replays · Thought deceleration · Focus enhancement · Information processing enhancement · Delusions · Amnesia · Delirium
Cognitive euphoria · Cognitive flexibility · Introspection enhancement · Multiple thought streams · Openness enhancement · Thought connectivity · Memory suppression · Thought loops · Cognitive fatigue · Cognitive impairment · Confusion · Focus suppression · Increased nature relatedness · Information processing suppression · Memory fragmentation · Thought disorganization · Analysis enhancement · Creativity enhancement · Analysis suppression · Cognitive dysphoria · Humor enhancement · Motivation suppression · Synchronicity · Language suppression · Memory replays · Thought deceleration · Focus enhancement · Information processing enhancement · Amnesia · Delirium
Empathy enhancement · Simultaneous emotions · Catharsis · Dysphoria · Irritability
Irritability
Communication suppression · Social connection · Trust enhancement · Communication enhancement · Sociability enhancement · Sociability suppression · Social disconnection · Flow state · Boundary dissolution · Identity alteration · Cognitive disconnection · Ego dissolution
Sociability enhancement · Sociability suppression · Social disconnection · Flow state · Boundary dissolution · Identity alteration · Cognitive disconnection · Ego dissolution
Time cessation
Entity contact · Non-dual awareness · Cessation · Death-rebirth sequence · Voidness · Near-death experience
Voidness · Near-death experience
Recursive awareness
Timeline
First alerts appear 30–90 minutes after ingestion: mild mood shift, slight body awareness, faint colour brightening. Easily overlooked or attributed to anticipation.
Effects build steadily over 45–90 minutes. Nausea peaks during this phase and is among the most common complaints. Colour enhancement and geometric patterning begin to emerge.
Maximum intensity sustained for 2–4 hours. Visual patterning, colour saturation, empathogenic warmth, and introspective depth reach their apex. Thought connectivity and emotional intensity are highest.
Effects remain clearly present but gradually diminishing over 2–3 hours. Visual effects soften. Empathogenic and introspective qualities persist.
A gentle descent over 1. 5–3 hours. Perceptual effects fade to occasional traces.
Residual mood elevation, reflective thinking, and mild fatigue may persist for 4–12 hours after primary effects resolve. Sleep quality may be reduced.
⚠ Do not drive or operate heavy machinery for at least 24 hours after ingestion, as subtle cognitive impairment may persist beyond subjective awareness.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- DOI · 2C-B · mesc
Toxicity
Acute Toxicity
Three deaths occurred in the United States between late 2000 and April 2001.[8][2][9] All involved insufflated doses of ≥30 mg and/or co-ingestion of MDMA or stimulants — one confirmed single-substance death followed insufflation of an excessive dose.[2]
No deaths have been reported from oral use at conventional doses (10–30 mg) without co-intoxicants. No lethal dose has been established in any species.
Cell-Based Toxicity
Laboratory tests on neuronal cell cultures found cell death and energy depletion at high concentrations.[22] These concentrations far exceeded estimated brain levels at typical human doses — direct translation to real-world risk is not established.
Psychological Risks
Anxiety and panic attacks are documented at higher doses,[2][5] and paranoid thinking has been noted.[2] Overwhelming visual intensity at strong doses can trigger acute psychological crisis.
The 8–15 hour duration means anyone experiencing distress faces a prolonged period with no pharmacological way to end the experience — benzodiazepines can reduce anxiety but not terminate it. No published data address psychosis risk, lasting perceptual disturbances, or worsening of pre-existing psychiatric conditions.
Tolerance and Dependence
Tolerance builds rapidly through serotonin downregulation, and cross-tolerance with other phenethylamine psychedelics is complete — increasing the dose cannot overcome it.[6] Phenethylamine psychedelics develop tolerance faster than tryptamines.[6]
Community estimates suggest tolerance clears in about 7 days,citation needed but this has not been confirmed experimentally. The compound shows no meaningful activity at the reward circuits involved in addiction,[23] and is not considered habit-forming.inferred
Drug Interactions
The combination of serotonin receptor activation and monoamine oxidase inhibition gives 2C-T-7 an elevated interaction risk compared to phenethylamine psychedelics without MAO activity.
MAO Inhibitors
2C-T-7 is broken down primarily by MAO enzymes.[19] Adding a pharmaceutical or natural MAO inhibitor (phenelzine, tranylcypromine, harmine, harmaline) blocks its main elimination route, causing unpredictable spikes in blood levels. Combined with the compound's own MAO-inhibiting and serotonin-activating properties, this creates severe serotonin syndrome risk.[7][19]
MDMA
Two of three documented deaths involved MDMA co-ingestion.[9][24] MDMA floods the brain with serotonin; combined with 2C-T-7's receptor activation and MAO inhibition, the serotonergic load compounds dangerously. Cardiovascular stress is amplified.
Sympathomimetic Stimulants
One fatality involved co-ingestion of ephedrine.[9] Amphetamines, cocaine, and similar stimulants increase cardiovascular strain alongside 2C-T-7's psychedelic state.
Serotonergic Medications
SSRIs, SNRIs, lithium, tramadol, linezolid, and dextromethorphan all raise the risk of dangerous serotonin overload when combined with 2C-T-7.[25] SSRIs may also blunt 2C-T-7's effects through long-term serotonin receptor downregulation.
CYP2D6 Interactions
CYP2D6 plays a secondary role in 2C-T-7 metabolism.[19] Strong CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion, quinidine) may slow clearance, but this is less significant than MAO pathway interactions.
Contraindications
Absolute contraindications: concurrent MAO inhibitor use,[19][7] concurrent MDMA use,[9] personal or family history of psychotic disorders,safety citation needed and concurrent lithium use.safety citation needed
Relative contraindications: concurrent SSRI or SNRI use,[25] cardiovascular disease, epilepsy or seizure disorders, liver impairment, pregnancy and breastfeeding (no safety data), and adolescence (one fatality involved a 17-year-old[24]).
Harm Reduction[edit]
Forms & Identification
Most 2C-T-7 encountered historically appeared as a white to off-white powder or pressed tablets. It is visually indistinguishable from dozens of other phenethylamines — reagent testing before use is essential.
The gap between an active oral dose and the insufflated doses associated with fatalities is measured in milligrams. Precision weighing with a milligram-scale balance (±1 mg) is non-negotiable for powder forms. Material that cannot be weighed accurately should not be used.
Guidelines
- Test all material with reagent kits before use. A milligram-scale balance (±1 mg precision) is essential — never estimate powder doses by eye.
- Start with a low oral dose and wait at least 2.5 hours before considering any adjustment. Onset is slow and variable; premature redosing is a primary risk factor for overdose.
- Oral administration is strongly preferred. All three documented fatalities involved insufflation, which delivers a more rapid and less controllable dose escalation.
- Eat lightly 2–3 hours beforehand to reduce nausea without dosing on a full stomach.
- Keep benzodiazepines accessible as a safety net for unmanageable anxiety (e.g. diazepam 5–10 mg oral).
- Plan for the full duration — 8–15 hours is a significant commitment spanning daylight and nighttime hours.
Set & Setting
The 8–15 hour duration demands realistic planning. Choose a familiar, safe environment with no obligations for the full day and the following morning. A sober companion is strongly recommended, especially at higher doses where anxiety and overwhelming visuals become more likely.
Nausea during onset is common. Having water, ginger, and a quiet space available reduces discomfort during the come-up.
Aftercare & integration. The extended duration can leave the body and mind exhausted. Prioritize sleep, hydration, and light nutrition in the 24 hours following the experience. Mild mood shifts — elevated or subdued — are common for 1–2 days afterward.
For psychologically significant experiences, journaling within the first 48 hours helps capture insights before they fade. If the experience was distressing or brought up difficult material, talking with a trusted person or a psychedelic integration therapist can help. Persistent anxiety, depersonalization, or visual disturbances lasting more than a week warrant professional consultation.
Recovery & Support
2C-T-7 is not considered physically addictive, and rapid tolerance limits compulsive daily use. If use has become a pattern of avoidance or emotional regulation, peer support communities such as psychedelic integration circles or harm reduction organizations can help.
For broader substance use concerns, SAMHSA's National Helpline (1-800-662-4357) provides free, confidential referrals.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Uncomfortable anxiety and nausea are common and usually pass. Seek immediate help if any of the following occur: seizures, loss of consciousness, rigid or jerking muscles, chest pain, severe confusion with inability to communicate, self-harm behavior, or body temperature that feels dangerously hot to touch.
Immediate steps:
- Call emergency services immediately if seizures, unconsciousness, or severe overheating occur.
- Place an unconscious but breathing person in the recovery position (on their side, airway clear).
- Do not restrain a conscious person unless they are in immediate danger of harming themselves.
- Keep the environment calm, quiet, and cool. Remove excess clothing if overheating.
- Do not induce vomiting.
What to tell the dispatcher: Name the substance (2C-T-7 — a psychedelic phenethylamine), approximate dose and time of ingestion, route of administration, any other substances taken, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
2C-T-7 is controlled internationally under the United Nations 1971 Convention on Psychotropic Substances and is independently scheduled in most major jurisdictions.[12][8]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Temporary placement September 20, 2002;[10] permanent March 18, 2004.[3] No accepted medical use per DEA. |
| European Union | Controlled per Council Decision 2003/847/JHA | EU-wide control measures enacted November 27, 2003 following EMCDDA risk assessment.[11] |
| United Kingdom | Controlled under MDA 1971; Psychoactive Substances Act 2016 | Covered by generic phenethylamine definitions in the Misuse of Drugs Act 1971; additional blanket coverage under the Psychoactive Substances Act 2016.[8] |
| Germany | Anlage I BtMG (Schedule I equivalent) | Controlled since July 1, 2001.citation needed |
| Netherlands | Banned | Among the first jurisdictions to ban 2C-T-7 from smart shop sale, circa 2000–2001.citation needed |
| Canada | Schedule III (CDSA) | Controlled since October 12, 2016.citation needed |
| Australia | Analog drug laws | Not specifically named; controlled as a structural analog of scheduled phenethylamines.citation needed |
| United Nations | Schedule II (1971 Convention) | Added October 2009.citation needed |
2C-T-7 was among nine phenethylamines submitted for EMCDDA risk assessment, with all except MBDB recommended for EU-wide control.[8]
references
- [1]
- [2]
- [3]
- [4]
- [5]
- [6] ^abcSmith DA, Bailey JM, Williams D, Fantegrossi WE (2014) Tolerance and cross-tolerance to head twitch behavior elicited by phenethylamine- and tryptamine-derived hallucinogens in mice. — The Journal of pharmacology and experimental therapeutics doi:10.1124/jpet.114.219337